Neuroleptic Malignant Syndrome
10 drugs7,000 FAERS reportsMedDRA PT
GET
/api/v1/reaction/neuroleptic-malignant-syndromeReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D009459
A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
Source: U.S. National Library of Medicine — MeSH (Neuroleptic Malignant Syndrome)
Drugs reporting Neuroleptic Malignant Syndrome (10)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Dantrolene1719.8%
- 2Fluphenazine448.3%
- 3Haloperidol1,7466.5%
- 4Pimozide296.3%
- 5Chlorpromazine2934.2%
- 6Loxapine1463.9%
- 7Amisulpride2223.8%
- 8Bromocriptine243.7%
- 9Olanzapine2,6722.5%
- 10Lactate1,6532.2%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Neuroleptic Malignant Syndrome as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Clozapine Withdrawal-Induced Catatonia with Overlapping Features of Neuroleptic Malignant Syndrome: a Case Report.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2026 · Softic R, Tufekcic A, Klebic J, et al.PMID 41939501DOI 10.5455/medarh.2026.80.94-95
- Intensive Care Management and Outcomes of Neuroleptic Malignant Syndrome: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026 · Özdemir F, Birtane D, Yılmaz N, et al.PMID 41752777DOI 10.3390/medicina62020378
- Clinical Outcomes of Dantrolene in Neuroleptic Malignant Syndrome: A Nationwide Retrospective Study.Acta psychiatrica Scandinavica · 2026 · Suekane A, Senda A, Morishita K, et al.PMID 41608809DOI 10.1111/acps.70073
- [Experience of Neuroleptic Malignant Syndrome After Operation:Total Arch Replacement for Stanford Type A Acute Aortic Dissection:Report of a Case].Kyobu geka. The Japanese journal of thoracic surgery · 2025 · Nosaka Y, Ikeda MPMID 41253318
- Lorazepam in Managing Atypical Neuroleptic Malignant Syndrome: A Systematic Review of Case Reports.The western journal of emergency medicine · 2025 · Chen A, Bae MPMID 41192984DOI 10.5811/westjem.41514
- Neuroleptic Malignant Syndrome with Low-dose Quetiapine After Venlafaxine Withdrawal: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025 · Özden HC, Gürel ŞCPMID 41070489DOI 10.5080/u27497
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.